Bronchiolitis obliterans organizing pneumonia in renal transplant patients

Abstract

Bronchiolitis obliterans organizing pneumonia (BOOP) is a syndrome with distinct clinical, radiological, and histological features. The radiographic changes of BOOP vary from multiple patchy, alveolar, or ground‐glass infiltrates to diffuse reticulonodular opacities. The most frequently observed CT features are areas of lung consolidation and ground‐glass opacity often with a subpleural distribution and small nodules; in addition, bronchial wall thickening and bronchodilatation can be seen. The exact pathogenesis of BOOP after organ transplantation remains to be clarified. Some researchers have suggested that BOOP is a non‐specific reaction to injury; rejection is the most common injury in lung and kidney transplant recipients.

Post-CMV organizing pneumonia – An unusual presentation 10 years after kidney transplantation

“…[ 10 ] and Hasni et al . [ 11 ] In other cases, sirolimus was the probable agent implicated in the occurrence of organizing pneumonia. [ 12 13 14 15 ] Recovery in these cases required discontinuation of sirolimus and escalation of steroid doses.…”

In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets

“…However, some authors have reported a high rate of discontinuation secondary to side effects after the introduction of this drug [ 5 , 6 , 7 ]. Among them, pneumonitis or interstitial lung disease with a range of pulmonary histopathologic changes (including alveolar hemorrhage, pulmonary alveolar proteinosis, focal fibrosis, bronchiolitis obliterans organizing pneumonia) have been largely reported in clinical records and they have been associated with worsened patients’ clinical outcomes and drug discontinuation [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. The incidence of this complications is 2–11%, frequently reported between 1 and 51 months after the beginning of mTOR inhibitor therapy [ 17 , 18 , 19 ].…”